^
    12ms
    OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Debiopharm International SA | Recruiting --> Active, not recruiting | Phase classification: P1b --> P1 | Trial completion date: Jun 2025 --> Dec 2024 | Trial primary completion date: May 2025 --> Nov 2024
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide 3-month extended release (Debio 4126) • octreotide acetate
    over1year
    OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov)
    P1b, N=30, Recruiting, Debiopharm International SA | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> May 2025
    Trial completion date • Trial primary completion date
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide 3-month extended release (Debio 4126) • octreotide acetate
    2years
    OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov)
    P1b, N=30, Recruiting, Debiopharm International SA | Trial completion date: Jul 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide 3-month extended release (Debio 4126) • octreotide acetate
    over2years
    OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov)
    P1b, N=30, Recruiting, Debiopharm International SA | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide 3-month extended release (Debio 4126) • octreotide acetate
    over2years
    OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov)
    P1b, N=30, Not yet recruiting, Debiopharm International SA | Trial completion date: Dec 2024 --> Jul 2024
    Trial completion date
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide 3-month extended release (Debio 4126) • octreotide acetate
    over2years
    OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov)
    P1b, N=30, Not yet recruiting, Debiopharm International SA
    New P1 trial
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide 3-month extended release (Debio 4126) • octreotide acetate